Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer

Cancer Letters

Volumn 335, Issue 2, 2013, Pages 479-486

  Kim, Se Lim ^a   Kim, Seong Hun ^a   Trang, Kieu Thi Thu ^a   Kim, In Hee ^a   Lee, Seung Ok ^a   Lee, Soo Teik ^a   Kim, Dae Ghon ^a   Kang, Sang Beom ^b   Kim, Sang Wook ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

Author keywords

5 Fluorouracil; Anti cancer; Colorectal cancer; Combination therapy; Parthenolide

Indexed keywords

CASPASE 3; CASPASE 9; CYTOCHROME C; FLUOROURACIL; LIPOCORTIN 5; PARTHENOLIDE; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOCHROMES C; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; MITOCHONDRIA; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; SESQUITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878240247     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.03.007     Document Type: Article

References (43)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA: A Cancer Journal for Clinicians 2009, 59:225-249.
2. Meyerhardt J.A., Mayer R.J. Systemic therapy for colorectal cancer. The New England Journal of medicine 2005, 352:476-487.
3. Tebbutt N.C., Cattell E., Midgley R., Cunningham D., Kerr D. Systemic treatment of colorectal cancer. European Journal of Cancer 2002, 38:1000-1015.
4. Kuhn J.G. Fluorouracil and the new oral fluorinated pyrimidines. The Annals of pharmacotherapy 2001, 35:217-227.
5. Nita M.E., Nagawa H., Tominaga O., Tsuno N., Fujii S., Sasaki S., Fu C.G., Takenoue T., Tsuruo T., Muto T. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. British Journal of Cancer 1998, 78:986-992.
6. Knight D.W. Feverfew: chemistry and biological activity. Natural Product Reports 1995, 12:271-276.
7. Carlisi D., D'Anneo A., Angileri L., Lauricella M., Emanuele S., Santulli A., Vento R., Tesoriere G. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. Journal of Cellular Physiology 2011, 226:1632-1641.
8. Sohma I., Fujiwara Y., Sugita Y., Yoshioka A., Shirakawa M., Moon J.H., Takiguchi S., Miyata H., Yamasaki M., Mori M., Doki Y. Parthenolide, an NF-κB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics and Proteomics 2011, 8:39-47.
9. Zanotto-Filho A., Braganhol E., Schroder R., de Souza L.H., Dalmolin R.J., Pasquali M.A., Gelain D.P., Battastini A.M., Moreira J.C. NF-κB inhibitors induce cell death in glioblastomas. Biochemical Pharmacology 2011, 81:412-424.
10. Zhao L.J., Xu Y.H., Li Y. Effect of parthenolide on proliferation and apoptosis in gastric cancer cell line SGC7901. Journal of Digestive Diseases 2009, 10:172-180.
11. Park J.H., Liu L., Kim I.H., Kim J.H., You K.R., Kim D.G. Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. Cancer Research 2005, 65:2804-2814.
12. Dai Y., Guzman M.L., Chen S., Wang L., Yeung S.K., Pei X.Y., Dent P., Jordan C.T., Grant S. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology 2010, 151:70-83.
13. Sun Y., St Clair D.K., Xu Y., Crooks P.A., St Clair W.H. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Research 2010, 70:2880-2890.
14. Zhang S., Ong C.N., Shen H.M. Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. Cancer Letters 2004, 211:175-188.
15. Kim S.L., Trang K.T., Kim S.H., Kim I.H., Lee S.O., Lee S.T., Kim D.G., Kim S.W. Parthenolide suppresses tumor growth in a xenograft model of colorectal cancer cells by inducing mitochondrial dysfunction and apoptosis. International Journal of Oncology 2012.
16. Fang L.J., Shao X.T., Wang S., Lu G.H., Xu T., Zhou J.Y. Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-κB activation and induction of apoptosis. Planta Medica 2010, 76:258-264.
17. Gao Z.W., Zhang D.L., Guo C.B. Paclitaxel efficacy is increased by parthenolide via nuclear factor-κB pathways in in vitro and in vivo human non-small cell lung cancer models. Current Cancer Drug Targets 2010, 10:705-715.
18. Yun B.R., Lee M.J., Kim J.H., Kim I.H., Yu G.R., Kim D.G. Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells. Experimental and Molecular Medicine 2010, 42:787-797.
19. Lee C.S., Kim Y.J., Lee S.A., Myung S.C., Kim W. Combined effect of Hsp90 inhibitor geldanamycin and parthenolide via reactive oxygen species-mediated apoptotic process on epithelial ovarian cancer cells. Basic and Clinical Pharmacology and Toxicology 2012, 111:173-181.
20. Yip-Schneider M.T., Nakshatri H., Sweeney C.J., Marshall M.S., Wiebke E.A., Schmidt C.M. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells. Molecular Cancer Therapeutics 2005, 4:587-594.
21. Fulda S., Debatin K.M. Death receptor signaling in cancer therapy, Current medicinal chemistry. Anti-Cancer Agents 2003, 3:253-262.
22. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
23. Bates R.C., Edwards N.S., Burns G.F., Fisher D.E. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Research 2001, 61:5275-5283.
24. Leichman C.G., Chansky K., Macdonald J.S., Doukas M.A., Budd G.T., Giguere J.K., Abbruzzese J.L. Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a southwest oncology group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. Investigational New Drugs 2002, 20:419-424.
25. Levi F.A., Zidani R., Vannetzel J.M., Perpoint B., Focan C., Faggiuolo R., Chollet P., Garufi C., Itzhaki M., Dogliotti L., et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. Journal of the National Cancer Institute 1994, 86:1608-1617.
26. Melen-Mucha G., Balcerczak E., Mucha S., Panczyk M., Lipa S., Mirowski M. Expression of p65 gene in experimental colon cancer under the influence of 5-fluorouracil given alone and in combination with hormonal modulation. Neoplasma 2004, 51:319-324.
27. Richards F., Case L.D., White D.R., Muss H.B., Spurr C.L., Jackson D.V., Cooper M.R., Zekan P., Cruz J., Stuart J.J., et al. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the piedmont oncology association. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1986, 4:565-570.
28. Aquino A., Prete S.P., Greiner J.W., Giuliani A., Graziani G., Turriziani M., De Filippi R., Masci G., Bonmassar E., De Vecchis L. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 1998, 4:2473-2481.
29. Obi S., Yoshida H., Toune R., Unuma T., Kanda M., Sato S., Tateishi R., Teratani T., Shiina S., Omata M. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006, 106:1990-1997.
30. Zhang S., Ong C.N., Shen H.M. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Letters 2004, 208:143-153.
31. Woynarowski J.M., Konopa J. Inhibition of DNA biosynthesis in HeLa cells by cytotoxic and antitumor sesquiterpene lactones. Molecular Pharmacology 1981, 19:97-102.
32. Choi J.H., Yoon J.S., Won Y.W., Park B.B., Lee Y.Y. Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 2012, 120:597-604.
33. Wen J., You K.R., Lee S.Y., Song C.H., Kim D.G. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. The Journal of Biological Chemistry 2002, 277:38954-38964.
34. Schmoll H.J., Buchele T., Grothey A., Dempke W. Where do we stand with 5-fluorouracil?. Seminars in Oncology 1999, 26:589-605.
35. Pritchard D.M., Potten C.S., Hickman J.A. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Research 1998, 58:5453-5465.
36. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299.
37. Sionov R.V., Haupt Y. The cellular response to p53: the decision between life and death. Oncogene 1999, 18:6145-6157.
38. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275:967-969.
39. De Angelis P.M., Stokke T., Thorstensen L., Lothe R.A., Clausen O.P. Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype. Molecular Pathology: MP 1998, 51:254-261.
40. Simms L.A., Radford-Smith G., Biden K.G., Buttenshaw R., Cummings M., Jass J.R., Young J., Meltzer S.J., Leggett B.A. Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. Oncogene 1998, 17:2003-2008.
41. Ogura E., Senzaki H., Yamamoto D., Yoshida R., Takada H., Hioki K., Tsubura A. Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. Oncology Reports 1999, 6:365-369.
42. Sturm I., Kohne C.H., Wolff G., Petrowsky H., Hillebrand T., Hauptmann S., Lorenz M., Dorken B., Daniel P.T. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1999, 17:1364-1374.
43. Maurer C.A., Friess H., Buhler S.S., Wahl B.R., Graber H., Zimmermann A., Buchler M.W. Apoptosis inhibiting factor Bcl-xL might be the crucial member of the Bcl-2 gene family in colorectal cancer. Digestive Diseases and Sciences 1998, 43:2641-2648.